摘要
目的探讨阿帕替尼联合卡培他滨治疗胃癌患者的临床疗效及其对血清肿瘤标志物水平的影响。方法回顾性分析2016年11月-2020年11月中国科学院中关村医院收治的80例胃癌患者,根据治疗方法将患者分为对照组(41例)和观察组(39例)。对照组患者口服卡培他滨片,1000 mg/m^(2),2次/d,治疗2周后停药1周,21 d为1个周期。观察组在对照组的基础上口服甲磺酸阿帕替尼片,500 mg/次,1次/d,治疗2周,21 d为1个周期。患者需维持用药3个周期。观察两组患者的临床疗效,同时比较两组治疗前后的血清肿瘤标志物[糖类抗原724(CA724)、糖类抗原19-9(CAl9-9)、糖类抗原125(CA125)、癌胚抗原(CEA)]、血清Th1/Th2细胞因子[γ干扰素(IFN-γ)、白细胞介素-2(IL-2)、白细胞介素-4(IL-4)、白细胞介素-10(IL-10)]水平。结果治疗后,观察组总有效率为84.6%,显著高于对照组的48.8%(P<0.05)。治疗后,两组CA724、CAl9-9、CA125和CEA水平均显著降低(P<0.05);治疗后,观察组血清肿瘤标志物水平显著低于对照组(P<0.05)。治疗后,两组IFN-γ、IL-2水平显著升高,IL-4、IL-10水平显著降低(P<0.05);且观察组血清Th1/Th2细胞因子水平显著优于对照组(P<0.05)。结论阿帕替尼联合卡培他滨治疗胃癌具有明显的治疗效果,可以有效降低机体中的血清肿瘤标志物水平,调节机体中的血清Th1/Th2细胞因子水平,同时没有增加不良反应,安全性高,值得推广借鉴。
Objective To investigate the clinical efficacy of apatinib combined with capecitabine in treatment of gastric cancer patients and its effect on serum tumor markers.Methods Eighty patients with gastric cancer admitted to Zhongguancun Hospital of Chinese Academy of Sciences from November 2016 to November 2020 were retrospectively analyzed,and the patients were divided into control group(41 cases)and observation group(39 cases)according to treatment methods.Patients in the control group were po administered with Capecitabine Tablets,1000 mg/m^(2),twice daily.After 2 weeks of treatment,the drug was stopped for 1 week,21 days as a cycle.Patients in the observation group were po administered with Apatinib Mesylate Tablets on the basis of control group,500 mg/time,once daily for 2 weeks,21 d as a cycle.Patients were required to maintain medication for 3 cycles.After treatment,the clinical efficacy of two groups was observed.And the serum tumor markers(CA724,CAL9-9,CA125,CEA),serum Th1/Th2 cytokines(IFN-γ,IL-2,IL-4,IL-10)before and after treatment were compared between two groups.Results After treatment,the total effective rate of observation group was 84.6%,which was significantly higher than 48.8%of control group(P<0.05).After treatment,the levels of CA724,CAL9-9,CA125,and CEA in two groups were significantly decreased(P<0.05).After treatment,the level of serum tumor markers in observation group was significantly lower than that in control group(P<0.05).After treatment,the levels of IFN-γand IL-2 in two groups were significantly increased,while the levels of IL-4 and IL-10 were significantly decreased(P<0.05).The serum Th1/Th2 cytokine level of observation group was significantly better than that of control group(P<0.05).Conclusion Apatinib combined with capecitabine in treatment of gastric cancer has obvious therapeutic effect,can effectively reduce the level of serum tumor markers,regulate the level of serum Th1/Th2 cytokines,without increasing adverse reactions,high safety,worthy of promotion and reference.
作者
荣秀梅
张雅月
吕红琼
RONG Xiumei;ZHANG Yayue;LV Hongqiong(Zhongguancun Hospital,Chinese Academy of Sciences,Beijing 100192,China;Dongzhimen Hospital,Beijing University of Chinese Medcine,Beijing 100007,China;Luoyang Central Hospital,Luoyang 471000,China)
出处
《药物评价研究》
CAS
2021年第8期1746-1750,共5页
Drug Evaluation Research
